Well everyone does appreciate your dedication.

The 961 is not accurate

George is out for his own gain just like Every other investor that puts money in. So when investing in these companies do your due diligence and invest with care.

Cxbs looking good. Who ever is shorting it will cover soon. I'm sure its just a market maker.

The company looks to be moving forward as planned. I think the press release today was positive. Hopefully they can over come the bad moves from before that you guys keep mentioning.

Irvine, CA -- March 8, 2018 -- InvestorsHub NewsWire -- Corix Bioscience Inc. (OTCQB: CXBS), an emerging developer of proprietary cannabis and industrial hemp strains earmarked specifically for use in important healthcare applications, today announced that it has executed a definitive agreement to acquire a 60% interest in OG Group LLC, positioning Corix to play a leading role in the California cannabis market.

Corix CEO Michael Ogburn commented, “We are pleased to team up with the highly-regarded industry leaders at OG Group. This acquisition allows us to put licenses Corix already owns to significant use. OG Group will be utilizing more than $5 million worth of specialty processing equipment to service customer orders. Together we expect to positively impact the entire ecosystem of this business.”

OG Group is purchasing a principal operations facility in Adelanto, California. The building has 1,800 square feet immediately available for processing activities, with substantial room for enlarging to meet customer needs. The real estate also includes ~44,000 square feet that could be used for future cultivation. OG Group is funding all of the purchase and start-up costs of the Adelanto facility and real estate.

CEO Ogburn noted, “The legalization of medicinal and adult-use cannabis in California this year, paired with the cannabis licenses (cultivation, processing and distribution) that Corix holds in Adelanto, makes this acquisition particularly fortuitous and timely. In the context of a current highly-fragmented California market, the acquisition of OG Group could, within a short period of time, result in Corix being the leading cannabis extractor in the state.”

The all-stock acquisition of 60% of OG Group calls for 17,500,000 Corix common shares to be issued to the OG Group shareholders; with 5,000,000 shares issued upon closing the transaction, and 2,500,000 shares to be issued on each subsequent purchase anniversary for five years thereafter.

Further details of the acquisition will be contained in an 8-K filing with the SEC.

About OG Group

OG Group LLC was recently established by several experienced industry leaders who have revolutionized the cannabis distillery and refinery space. Their background in modern technology and molecular science has allowed them to serially invent ground-breaking products that dominate the market.

One recent innovation that has already generated enormous demand is a service designed to assist cultivators in adapting to the regulation changes in California. To protect consumers, the state has toughened its regulations on residual pesticide levels in cannabis. OG Group has developed a unique molecular procedure that removes the residual pesticides, allowing cultivators’ products to be compliant once again, and also safer for their customers. 

Utilizing science and technology, OG Group has become a leading innovator in the cannabis industry, achieving levels of quality that have redefined the standards for cannabis-related products.

About Corix

Corix Bioscience Inc. develops proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants that are free of any pathogen or disease. We grow these plants to maturity and extract the oils, which are the “medicine” part of the plants. Our market focus is on healthcare and we expect to release our initial brand-name products for distribution in the first half of this year.

Our principal executive offices are in Irvine, California. We grow industrial hemp on land we leased near Genoa, Nevada. We are purpose-driven. Our mission is to create superior-quality products in medical-grade facilities, better for both people and the environment. For more information, we invite you to visit us on the Web at www.corixbioscience.com.

Cautionary Note Regarding Forward-Looking Statements

Certain of the statements in this news release that are not statements of historical fact, including, but not limited to, those identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, and including statements related to expected market trends and the future business and financial performance of Corix Bioscience Inc., are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties.

Prospective investors are cautioned not to place undue reliance on any forward-looking statements. Statements made regarding the intent, belief or current expectations of Corix are based on assumptions that Corix management believes are reasonable in light of information available on the date hereof, but they are not guarantees of future performance and are subject to a wide range of known and unknown risks, uncertainties and other factors identified in periodic filings made by Corix with the Securities and Exchange Commission.

Actual future results may differ materially from those indicated by present forward-looking statements. Corix Bioscience Inc. disclaims any obligation to update or revise this news release to reflect any change in the company's expectations or any change in events or circumstances after the date hereof, except as required by law.

 

Company Contacts Media: Michael Ogburn,CEO Corix Bioscience Inc.(603) 551-5808 info@CorixBioscience.com Investor Relations: Tim Rieu,CEO Chesapeake Group, Inc.(410) 825-2930 info@chesapeakegp.com

Well I have to say that's some good DUE-DILIGENCE. Got know everything about these deals if anyone is gonna have a chance. this is one of the ones I'll look at to see if it makes it or not but the industry is a good one and with Lisences there is a good chance to make money.

Ya I see that but I'm trying to see of they are actually going to make money this year or not. So that's why I'm paying attention to.

In terms of international sales, Corix Bioscience spent the last three months of 2017 paving way for the global market. By acquiring Pharmaceutical Development Corp LTD in South Africa, Corix has attained the first license issued by the Government of Lesotho that enables them to import and the export cannabis and cannabis resin in various forms. Corix also has an export license that allows them to export cannabis and CBD products to approximately 30 plus different countries in the EU, Canada, Australia, Mexico, Brazil and New Zealand. In the past quarter, Corix also shipped out their first sample order to Switzerland, as a first step into the European market.

Well only time will prove that for now. What I see is

In terms of international sales, Corix Bioscience spent the last three months of 2017 paving way for the global market. By acquiring Pharmaceutical Development Corp LTD in South Africa, Corix has attained the first license issued by the Government of Lesotho that enables them to import and the export cannabis and cannabis resin in various forms. Corix also has an export license that allows them to export cannabis and CBD products to approximately 30 plus different countries in the EU, Canada, Australia, Mexico, Brazil and New Zealand. In the past quarter, Corix also shipped out their first sample order to Switzerland, as a first step into the European market.

In terms of international sales, Corix Bioscience spent the last three months of 2017 paving way for the global market. By acquiring Pharmaceutical Development Corp LTD in South Africa, Corix has attained the first license issued by the Government of Lesotho that enables them to import and the export cannabis and cannabis resin in various forms. Corix also has an export license that allows them to export cannabis and CBD products to approximately 30 plus different countries in the EU, Canada, Australia, Mexico, Brazil and New Zealand. In the past quarter, Corix also shipped out their first sample order to Switzerland, as a first step into the European market.

Where do you read that it’s not going to happen. I don’t see that ?

At the end of the day we have to focus on the facts the company has a Lisence in Nevada, California, Switzerland and Africa to sell CBD's that alone will be huge just give it time. Let's go CXBS!!

In the green today. People have to sell to get money out. Holding strong. Building up volume so hopefully that helps it move in the right direction. Let's go CXBS!!

Yep and as the volume increases in CXBS everyday we shall hopefully see some great new levels. Good luck to all!!

Why some much FUD that's a real purchase for cash they made. That's good news.

Great update today!

Corix Bioscience Quarterly Shareholder UpdateSource: InvestorsHub NewsWire

 

Irvine, CA -- February 06, 2018 -- InvestorsHub NewsWire -- Corix Bioscience Inc. (OTCQB: CXBS) has had a tremendous quarter to end the year of 2017, prompting this announcement to communicate current successes and future milestones.

Highlights from the past 3 months include:

Rewarding harvest of industrial hemp in Carson City, Nevada
Purchased $1mm worth of processing equipment fully in cash (without financing)
Acquired Pharmaceutical Development Corp LTD in Lesotho, South Africa
Shipped our first set of samples to Switzerland and began marketing in the European market
Created Joint Venture with ChampRX

With top leading industry experts on their agricultural team and advanced seed genetics, Corix had a banner late harvest in Carson City, Nevada to close out 2017. Corix was able to excel in both quality and quantity in the cultivation of industrial hemp. The rewarding harvest not only proved their capabilities in cultivation, but the substantial inventory also became a promising start for 2018.

Corix has also scaled their manufacturing divisions with major equipment purchases and upgrades. Corix has obtained over $1mm worth of proprietary and agricultural equipment, all paid in full and without financing. These upgrades include a new trimming line, a new packaging line, stripping equipment, drying and preservation systems, post-processing equipment for CBD isolate, and Genius extraction equipment. Machinery of this scale paired up with their strong raw inventory, Corix has increased their overall capacity, will allow them to complete demands they could not fulfill in the past, and facilitate the continuous new incoming orders.

In terms of international sales, Corix Bioscience spent the last three months of 2017 paving way for the global market. By acquiring Pharmaceutical Development Corp LTD in South Africa, Corix has attained the first license issued by the Government of Lesotho that enables them to import and the export cannabis and cannabis resin in various forms. Corix also has an export license that allows them to export cannabis and CBD products to approximately 30 plus different countries in the EU, Canada, Australia, Mexico, Brazil and New Zealand. In the past quarter, Corix also shipped out their first sample order to Switzerland, as a first step into the European market.

Corix also solidified their joint venture with ChampRX for its products. Corix will be their official CBD manufacturer and a 25% equity holder in ChampRX. Both companies will be ring sponsors for Shannon Briggs's next title fight. Corix will also have access to the marketing for ChampRX and its partners. Under the terms of the agreement, Corix will provide the science and manufacturing behind the products and ChampRX will market and promote the product.

ChampRX is composed of several current and former boxers. This includes many title holders including 2X Heavyweight Champion Shannon Briggs, 2X Heavyweight Champion Chris Byrd with several other Olympic and Boxing Champions including Lamon Brewster, Montell Griffin and Ray Mercer, each multiple boxing champion. For more information visit their website at ChampRXCBD.com.

Corix has had a promising fourth quarter with strong synergies carrying into 2018. Corix is more than well-prepared for the new year and is well on their way to achieve their ultimate goals.

About Corix Bioscience Inc;

Corix Bioscience, Inc. (“Corix”) is a fully reporting Wyoming corporation listed as OTCQB:CXBS.  Corix is the developer of proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants, with plans to patent the strains to be used in the pharmaceutical medical industries.

Our methods allow us to create and breed new and existing plant strains from tissue cells free of any pathogens or disease. We grow these plants to maturity and extract the oils which are the “medicine” part of the plant. Our sales are focused towards the medical industry and we are developing brand named products to be released in early 2018.

Company headquarters are in Phoenix, AZ and with our laboratory and processing facility in Carson City, NV and we grow in Genoa, NV. We are currently looking at expanding our footprint into Washington, Oregon, California and Arizona. The Company’s mission is to create clean and consistent products in medical grade facilities.  Consistency being the key which will ultima yield a safer and superior product, better for people and the environment. For more information, please visit Corix’s website at www.corixbioscience.com

Forward Looking Statement

This press release, and those statements regarding Corix Bioscience and the Company, contain forward-looking statements that relate to expectations, beliefs, projections, future plans and strategies, anticipated events and similar expressions.  Forward-looking statements may be identified by use of words such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," or "potential" or similar words or phrases which are predictions of or indicate future events or trends.  Statements such as those concerning potential acquisition activity, investment objectives, strategies, opportunities, other plans and objectives for future operations or economic performance are based on the Company's current expectations, plans, estimates, assumptions and beliefs that involve numerous risks and uncertainties.  You are cautioned not to place undue reliance on any forward-looking statements and the Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, future events or other changes.  Please refer to Company's filings with the Securities and Exchange Commission for further information.

SOURCE Corix Bioscience Inc.

Related Links

http://www.corixbioscience.com

I can clearly see some people have a thing against ogburn but other then that i think this company has alot of good things lined up and only time will prove that so lets see where Micheal leads this thing then we can point fingers if everything goes wrong. This industry is just begining so hopefully some good up side. Time will tell.

Great interview with Shannon Briggs the owner of ChampRX on RICH TV LIVE.

Let's try and keep it professional. No need for BS rumours. This company is on track for some good things.

This company is consistently coming out with new developments. We got a winner here folks.

Corix Bioscience Purchases Pharmaceutical Development Corp LTDSource: New Media Wire

November 07, 2017 08:00 ET

PHOENIX, AZ--(NewMediaWire - Nov 7, 2017) - Corix Bioscience Inc. (OTCQB: CXBS) has purchased 100% of Pharmaceutical Development Corp., allowing Corix to commence selling its proprietary cannabis products internationally.

Michael Ogburn, Corix Bioscience CEO, stated, "This is a defining moment for our company. It allows us to grow and manufacture cannabis in Lesotho and distribute our products to dozens of other countries. It will allow us to accelerate our growth very quickly. This deal will help us grow into the powerhouse company we anticipate to be in 2018." 

Pharmaceutical Development's manufacturing facility is in Lesotho, a landlocked country located in South Africa. It received the first cannabis license in all of South Africa. They have an export treaty that allows them to export cannabis and CBD oil to approximately 30 plus different countries in the EU, Canada, Australia, Mexico, Brazil and New Zealand.

About Corix Bioscience Inc.

Corix Bioscience Inc. ("Corix") is a Wyoming corporation and is fully reporting with the SEC and is listed as OTCQB: CXBS. Corix is the developer of proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants, with plans to patent the strains to be used in the pharmaceutical medical industries.

Our methods allow us to create and breed new and existing plant strains from tissue cells free of any pathogens or disease. We grow these plants to maturity and extract the oils which are the "medicine" part of the plant. Our sales are focused towards the medical industry and we are developing brand named products to be released in early 2018.

Corix has offices in Irvine, CA., Phoenix, Arizona, a laboratory and processing facility in Carson City, Nevada, a research and development grow operation in Adelanto, CA., and fields for growing the plants in Genoa, Nevada. We are currently looking at expanding our footprint into Washington, Oregon and Colorado. The Company's mission is to create clean and consistent products in medical grade facilities. Consistency being the key which will ultimately yield a safer and superior product, better for people and the environment. For more information, please visit Corix's website at www.corixbioscience.com

Forward Looking Statement

This press release, and those statements regarding IXB and the Company, contain forward-looking statements that relate to expectations, beliefs, projections, future plans and strategies, anticipated events and similar expressions. Forward-looking statements may be identified by use of words such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," or "potential" or similar words or phrases which are predictions of or indicate future events or trends. Statements such as those concerning potential acquisition activity, investment objectives, strategies, opportunities, other plans and objectives for future operations or economic performance are based on the Company's current expectations, plans, estimates, assumptions and beliefs that involve numerous risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements and the Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, future events or other changes. Please refer to Company's filings with the Securities and Exchange Commission for further information. 

 

 

CONTACT INFORMATION

 

Contact: 
Corix Bioscience Inc.
Christ Froese
623-551-5808
CFroese@CorixBioscience.com

Brokers and Analysts
Chesapeake Group
410-825-3930

PDXP: OTC Short Positions on 2017/07/14 16,660 16,660

PDXP: OTC Short Positions on 2017/07/14 16,660 16,660

PDX Partners, Inc. Common Stoc ("PDXP-0") - OTC Short Positions on 2017/07/14 16,660 16,660

Net Total Last Total Price Date Change Shorted Price Volume Range ---------------------------------------------------------------------------- 2017/07/14 16,660 16,660 - 113,300 0.01 - 0.01 2017/06/30 N/A 0 - 195,300 0.01 - 0.01 2017/06/15 N/A 2017/05/31 N/A 2017/05/15 N/A 2017/04/28 N/A 2017/04/14 N/A 2017/03/31 N/A * - Indicates that the closing price used is the last non-zero closing price and is not the closing

PDX Partners, Inc. Lowers authorized shares from
10,000,000,000 to 3,040,000,000
Enhances Net Stock Holder Equity
(Irvine, California, June 20, 2017)
PDX Partners, Inc. ("PDXP") (OTC: PDXP) a marketing and diversified holdings company,
announces that the board has recently amended the company’s Articles of Incorporation with the
State of Wyoming to reflect a substantial reduction of authorized shares In the amount of
6,960,000,000 shares. Said CEO Patrick Johnson: “As we continue to implement strategies to
further reducing the companies debt, the game plan will be to further decrease the number of shares
authorized as we believe a low number of authorized shares will allow us to sustain a good stock
price and build a solid market cap for the company in the long term.”
ABOUT PDX PARTNERS, INC.
PDX Partners, Inc. (OTC: PDXP) is a marketing and diversified holdings company dedicated to
creating stable revenues and shareholder value by marketing technologies and acquiring other
diversified long term growth assets. The company was founded in 1997.
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of
1934 that are based upon assumptions that in the future may prove not to have been accurate and are
subject to significant risks and uncertainties, including statements as to the future performance of
the company and the risks and uncertainties detailed from time to time in reports filed by the
company with the Securities and Exchange Commission. Statements contained in this release that
are not historical facts may be deemed to be forward-looking statements. Investors are cautioned
that forward-looking statements are inherently uncertain. Although the company believes that the
expectations reflected in its forward-looking statements are reasonable, it can give no assurance that
such expectations or any of its forward-looking statements will prove to be correct. Factors that
could cause results to differ include, but are not limited to, the company's ability to raise necessary
financing, retention of key personnel, timely delivery of inventory from the company's suppliers,
timely product development, product acceptance, and the impact of competitive services and
products, in addition to general economic risks and uncertainties.

Perfect time to load up while it's down.

Hey is a former NFL player so he should of some gold contacts don't you think?

PDX Partners, Inc. Signs LOI to Market Game Changing Energy Technology To Cannabis Sector

PORTLAND, OR--(Marketwired - Jun 7, 2017) - PDX Partners, Inc. (OTC PINK: PDXP), a marketing and diversified holdings company, announces that it has executed a Letter of Intent with Green Flow Technology to market Green Flow's proprietary energy efficiency technology in North America. Green Flow has proprietary rights to the only technology on the market that has multiple patented components which create a new form of energy in the form of AC and DC flowing on existing wires. This new energy effectively "turbo charges" low voltage battery power to unprecedented levels. The proprietary Green Flow bulbs are specifically designed for high yield, healthy plant growth: "battery powered," low voltage, energy efficient, low heat, customizable UV and color spectrum, specific PAR values, automatic dimming controls, and built in emergency backup. The Green Flow bulbs are a few months away from being fully solar powered.

In addition to the Green Flow bulbs, the additional proprietary components include a Core System which includes multi-patented Charger, Efficiency Control Unit, Booster, and Energy storage bank. Green Flow's technology includes low voltage DC bulbs that are low heat, high output, and have customizable UV and color spectrums, i.e., "battery powered" lighting systems. Green Flow bulbs are based on an energy platform that is "plug and play." The Green Flow energy system is modular meaning that it can be expanded via additional modules to power any sized facility. Further, once the Core System is installed, the Green Flow's future pipeline of modules easily attach to expand the system's energy benefits, e.g.: Solar Module to create "solar powered" lighting, HVAC Module to create "solar powered" air conditioning, to effectively allow any grower to remove, most if not all, of their major energy uses off grid.

"This technology will forever change the cannabis industry as we know it today," said PDX Partners CEO Patrick Johnson. "The most significant component in the cannabis cultivation industry is lighting and power. With Green Flow bulbs and its ground breaking energy efficiency technology we have the ability to provide combined lighting and power packages that allow cultivators the chance to operate their facilities completely off the electrical grid. We are excited to be a part of penetrating the cannabis market with this technology as we believe it separates us from any and all competitors," said Johnson.

About Green Flow.
Green Flow has proprietary rights to technology which has 29 patents already issued worldwide and numerous more pending. Green Flow bulbs and foundational technology are a game changer. There is no other technology on the market that has patented components that create a new energy in the form of AC and DC flowing on existing wires. Further, as a "plug and play" system, additional components are simply plugged into the installed Green Flow energy core components to expand the system to accommodate any sized facility, i.e., larger facilities with higher power needs are simply addressed by sliding in a few more components to the Green Flow energy components. Most amazing is that because the system is modular, additional Green Flow energy modules covering other applications are also simply plugged into any installed Green Flow core system to upgrade and innovate and fulfill other energy needs, e.g., Solar Module, HVAC Module, which when combined with the core energy system, can create a potentially off grid grow facility.

About PDX Partners
PDX Partners, Inc. (OTC PINK: PDXP) is a marketing and diversified holdings company dedicated to creating stable revenues and shareholder value by marketing technologies and acquiring other diversified long term growth assets. The company was founded in 1997.

Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.

For more information please contact:
PDX Partners, Inc.
Patrick J. Johnson
Chief Executive Officer
(817) 705-1291
patrick@pdxpartners.com

Copyright © 2017 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

PDX Partners, Inc. Signs LOI to Market Game Changing Energy Technology To Cannabis Sector

PORTLAND, OR--(Marketwired - Jun 7, 2017) - PDX Partners, Inc. (OTC PINK: PDXP), a marketing and diversified holdings company, announces that it has executed a Letter of Intent with Green Flow Technology to market Green Flow's proprietary energy efficiency technology in North America. Green Flow has proprietary rights to the only technology on the market that has multiple patented components which create a new form of energy in the form of AC and DC flowing on existing wires. This new energy effectively "turbo charges" low voltage battery power to unprecedented levels. The proprietary Green Flow bulbs are specifically designed for high yield, healthy plant growth: "battery powered," low voltage, energy efficient, low heat, customizable UV and color spectrum, specific PAR values, automatic dimming controls, and built in emergency backup. The Green Flow bulbs are a few months away from being fully solar powered.

In addition to the Green Flow bulbs, the additional proprietary components include a Core System which includes multi-patented Charger, Efficiency Control Unit, Booster, and Energy storage bank. Green Flow's technology includes low voltage DC bulbs that are low heat, high output, and have customizable UV and color spectrums, i.e., "battery powered" lighting systems. Green Flow bulbs are based on an energy platform that is "plug and play." The Green Flow energy system is modular meaning that it can be expanded via additional modules to power any sized facility. Further, once the Core System is installed, the Green Flow's future pipeline of modules easily attach to expand the system's energy benefits, e.g.: Solar Module to create "solar powered" lighting, HVAC Module to create "solar powered" air conditioning, to effectively allow any grower to remove, most if not all, of their major energy uses off grid.

"This technology will forever change the cannabis industry as we know it today," said PDX Partners CEO Patrick Johnson. "The most significant component in the cannabis cultivation industry is lighting and power. With Green Flow bulbs and its ground breaking energy efficiency technology we have the ability to provide combined lighting and power packages that allow cultivators the chance to operate their facilities completely off the electrical grid. We are excited to be a part of penetrating the cannabis market with this technology as we believe it separates us from any and all competitors," said Johnson.

About Green Flow.
Green Flow has proprietary rights to technology which has 29 patents already issued worldwide and numerous more pending. Green Flow bulbs and foundational technology are a game changer. There is no other technology on the market that has patented components that create a new energy in the form of AC and DC flowing on existing wires. Further, as a "plug and play" system, additional components are simply plugged into the installed Green Flow energy core components to expand the system to accommodate any sized facility, i.e., larger facilities with higher power needs are simply addressed by sliding in a few more components to the Green Flow energy components. Most amazing is that because the system is modular, additional Green Flow energy modules covering other applications are also simply plugged into any installed Green Flow core system to upgrade and innovate and fulfill other energy needs, e.g., Solar Module, HVAC Module, which when combined with the core energy system, can create a potentially off grid grow facility.

About PDX Partners
PDX Partners, Inc. (OTC PINK: PDXP) is a marketing and diversified holdings company dedicated to creating stable revenues and shareholder value by marketing technologies and acquiring other diversified long term growth assets. The company was founded in 1997.

Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.

For more information please contact:
PDX Partners, Inc.
Patrick J. Johnson
Chief Executive Officer
(817) 705-1291
patrick@pdxpartners.com

Copyright © 2017 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

The companies at this level have no option for money. The debt is the only way. That's why it's so hard I'm sure.

What do you mean a new form of energy?

Yep this company is going places and right now the convertible guys are making the shares cheap for everyone to get in at a low cost. Good luck to all

NEWSROOM

Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer ImpactoJune 07, 2017

Nutra Pharma’s over the counter (OTC) products, Nyloxin® and Pet Pain-Away™, were featured on Univision’s Spanish-language news show, Primer Impacto on June 6, 2017.

June 7, 2017 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company and their products were featured in an interview aired last night on the Univision network’s Spanish-language news show, Primer Impacto (www.primerimpacto.com).

"Nutra Pharma was featured in an interview with NBC News-Miami recently that was picked up nationally by NBC affiliates. This has generated a lot of interest in the media and has led to additional interviews," commented Rik J Deitsch, CEO of Nutra Pharma. “Content providers for the leading Spanish-language news show, Primer Impacto, approached us about doing a much bigger feature about the Company and our drug products," he continued. "This report focusses on our OTC pain drugs: Nyloxin and Pet Pain-Away. These are clinically proven and all-natural products that are available today to deal with pain and inflammation in people and their pets," he concluded.

The interview was conducted by Kiki Garcia Montes with filming at Nutra Pharma’s laboratory facility and the reptile farm that houses their cobras for venom production.  Kiki, through her interviews, learned about cobra venom and its use as a potent pain-reliever (analgesic) and anti-inflammatory agent. There was also a demonstration of the venom milking process at the reptile farm that supplies cobra venom for the production of Nutra Pharma's OTC pain drugs, Nyloxin and Pet Pain-Away.

“This is our first foray into the Spanish-language market in the United States,” commented Mark Goldstein, Nutra Pharma’s acting Director of Sales. “We have already produced sales materials in Spanish as well as new Spanish packaging for our product registration efforts in Spain and Mexico,” he continued. “We will utilize this opportunity to begin aggressively marketing to the growing Latin population in the US and globally,” he concluded. 

The news segment can be viewed on Univision’s website:http://uni.vi/rXqB100Hgw0

And has also been posted to the show’s YouTube channel:

Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.  Nyloxin® is currently available as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

Pet Pain-Away™ is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats.

About Primer Impacto

Primer Impacto (First Impact) is a Spanish-language television news show broadcast by Univision in the U.S. and Mexico weekdays at 5pm ET. Primer Impacto is one of Univision's highest rated shows. It airs as a one hour news magazine show that features news, human interest, entertainment and sports content. It has been on the air since the mid 90's and has won numerous Emmy awards.
http://www.primerimpacto.com

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:

http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The news piece on Primer Impacto should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


             Select a Destination            Drug Discovery            Medical Devices            Newsroom                      Blogs            Investor Relations            Corporate Overview          

Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, inMusculoskeletal Health–a special section of theWashington Post. 

 

  June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies

May 23, 2017
Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures

  Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.    Privacy Policy

|

Code of Ethics

 Copyright © 2000-2017, Nutra Pharma Corporation. All Rights Reserved.

Finally it looks like things are moving in the right direction. Let's go PDXP!!

PDXP up 100% looks like it's getting ready to do something good.

Great interview. This company is definitely going places.

Lets get NPHC in the green!!!!

Alex is very smart guy and he is taking UATG to the next level.

No problem. I think this company has some good potential with Rik at CEO.

Great interview on richtvlive. Watch Rik speaking about all of NPHC's accomplishments.

The interview was good allowed me to see who is running the company and what direction it's going in. Great work Alex! Richtvlive.com is where you will find winners.

Rik is back on richtvlive tune in to watch the interview.